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We developed a chemically inducible cas9 (cicas9) and a droplet digital Pcr assay for double-strand breaks (dsB-ddPcr) to investigate the kinetics of cas9-mediated generation and repair of dsBs in cells. cicas9 is a rapidly activated, singlecomponent cas9 variant engineered by replacing the protein's rec2 domain with the Bcl-xl protein and fusing an interacting Bh3 peptide to the c terminus. cicas9 can be tunably activated by a compound that disrupts the Bcl-xl-Bh3 interaction within minutes. dsB-ddPcr demonstrates time-resolved, highly quantitative, and targeted measurement of dsBs. combining these tools facilitated an unprecedented exploration of the kinetics of cas9-mediated dnA cleavage and repair. We find that sgrnAs targeting different sites generally induce cleavage within minutes and repair within 1 or 2 h. however, we observe distinct kinetic profiles, even for proximal sites, and this suggests that target sequence and chromatin state modulate cleavage and repair kinetics.
Insights into the processes of DNA cleavage and repair have enabled the modification of Cas9, sgRNA, or experimental conditions to improve editing efficiency, specificity, and repair [1] [2] [3] [4] [5] . Nevertheless, large gaps remain in our understanding of the Cas9 editing process. In particular, little is known about the kinetics of Cas9-mediated DSB generation and repair in vivo. In vitro, the Cas9-sgRNA complex remains bound to cleaved DNA for ~6 h, which may delay surveillance and repair 1, 6 . Progress has been made in characterizing the target search dynamics of nuclease-null Cas9 (ref. 7) in cells, but how these findings relate to cleavage and repair kinetics of nuclease-competent Cas9 in vivo remains unclear.
Investigating Cas9 cleavage and repair kinetics in cells requires rapid and precise temporal control of Cas9 activity, so that cleavage can be activated at a defined point in time. With reported activation times ranging from 2 h to many hours, it is unclear whether existing inducible Cas9 variants become active rapidly enough (Supplementary Table 1 ) [8] [9] [10] [11] [12] [13] [14] [15] [16] . Additionally, a precise and rapidly inducible cas9 and dsB-ddPcr to probe editing kinetics temporally resolved method for quantifying DSB frequency is required, so that DNA cleavage can be measured in parallel with DNA editing. Existing methods evaluate DSBs on a locus-specific or genome-wide basis. However, these methods are qualitative or semiquantitative and are thus unsuitable for tracking Cas9 cleavage kinetics (Supplementary Table 2 ) [17] [18] [19] [20] [21] [22] [23] [24] [25] .
To overcome these limitations, we developed ciCas9 and DSBddPCR. ciCas9 is a rapidly inducible, single-component Cas9 variant engineered using a novel domain replacement strategy. ciCas9's level of basal activity is low, and it can be activated within minutes in a dose-dependent fashion. The architecture of ciCas9 also allows us to generate variants with increased specificity for on-target sites or even with lower basal activity. DSB-ddPCR demonstrates time-resolved, highly quantitative, targeted measurement of DSBs. The combined application of these two tools facilitated an unprecedented exploration of the kinetics of Cas9-mediated DSB generation and repair. We find that DSBs are generated rapidly (within 10 min for some sgRNAs), and that indels generally appear within 2 h. sgRNAs targeting different sites produce distinct DNA cleavage and repair kinetics, even when the sites are in close proximity. These findings suggest that target sequence and chromatin state modulate cleavage and repair kinetics.
results engineering a rapidly inducible cas9 variant
To generate ciCas9, we used the interaction between BCL-xL and a BH3 peptide as an intramolecular autoinhibitory switch 26 . Disruption of the BCL-xL-BH3 interaction by addition of the small molecule A-385358 (' A3') results in release of autoinhibition and activation of Cas9 (Fig. 1a) . Modeling suggested the nonessential Cas9 REC2 domain could be replaced with BCL-xL, which is similar in size to REC2 (Supplementary Fig. 1 ). Thus, we replaced the REC2 domain with BCL-xL, creating Cas9.BCL, which retains activity in the absence of A3 (Fig. 1b and Supplementary Fig. 2 ) 27 . A BH3 peptide was appended to either terminus of Cas9.BCL via linkers of 5 to 30 residues to introduce autoinhibition ( Supplementary Fig. 3 and Supplementary Note 1). The activity of each construct was assessed at the neutral locus AAVS1 in the absence or presence of A3. High-throughput sequencing revealed that C-terminal BH3 fusions resulted in A3-activated editing ( Supplementary Fig. 4) . We selected the shortest, fiveresidue linker for further study, and we subsequently refer to this construct as ciCas9.
Expression of ciCas9 in the absence of A3 resulted in minimal editing (0.32%, s.e.m. = 0.039%) compared to a no-sgRNA control (0.0033%; s.e.m. = 0.0010%) (Fig. 1c) . Addition of A3 generated a dose-dependent increase in editing, and this indicated that activity could be tuned by varying drug concentration. The highest concentration of A3, 10 µM, yielded a 24.7-fold (s.e.m. = 3.34) increase in editing compared to the no-drug control. This degree of activation is considerably higher than that reported for other inducible Cas9 systems 8, 10 . To demonstrate the generality of ciCas9, we assessed editing in HCT116 and U2OS cells. We observed A3-dependent editing, with minimal activity in the absence of drug (Supplementary Fig. 5 ).
cicas9 activation rapidly produces insertions or deletions
We next profiled ciCas9 insertion or deletion (indel) kinetics with four sgRNAs at three distinct loci (Fig. 1d) . AAVS1 and VEGFA sgRNA3 showed significant increases in indels within 30 min of A3 addition, and a significant increase in indels was present at all sites within 2 h (Supplementary Tables 3 and 4) . Thus, editing kinetics differ between sgRNA target sites at distinct loci. Kinetics also differ between sgRNA target sites at the same locus. The two VEGFA cleavage sites are only 1,091 nucleotides apart but have markedly different editing rates and editing frequency at 24 h; these differences could be caused by sequence and chromatin features that influence editing [28] [29] [30] . For example, VEGFA sgRNA3 has a higher guanine content than VEGFA sgRNA2 (55% versus 10%) and a higher predicted efficacy score based on the target and surrounding sequence (0.49 versus 0.29; Azimuth 2.0 on-target scoring model) 31 .
We next compared ciCas9 kinetics with the kinetics of other inducible systems (Supplementary Table 1 ). Some of these systems are much slower than ciCas9. For example, indels were reported after 9 h following activation of photoactivatable split Cas9 (paCas9) 9 . After activation of ciCas9, indels were detectable within 2 h using the same sgRNA and cell line ( Supplementary  Fig. 6a,b) . To compare ciCas9 with a recently described 4-hydroxytamoxifen-activated Cas9 (iCas9) 8 that is reported to be faster than both intein-Cas9 (ref. 10 ) and split-Cas9 (ref. 11), we measured ciCas9 editing kinetics using the same sgRNA with iCas9 (ref. 8) . ciCas9 generated a detectable increase in indels within 30 min (one-sided t-test; n = 3, P = 0.016) after A3 addition. The first measured time point for iCas9 was 2 h; but it is unclear whether the observed increase in indels is significant, because no statistical analyses were reported ( Supplementary Fig. 6c,d ).
dsB-ddPcr enables precise, site-specific quantitation of double-strand breaks In vivo, Cas9-mediated cleavage of DNA target sites is generally measured indirectly by quantifying indels. We developed DSBddPCR to directly and quantitatively measure the frequency of DSBs at a target site. DSB-ddPCR uses one primer pair that spans the sgRNA target site and another proximal pair that does not ( Fig. 2a; ref. 32 ). Amplification is detected using primer-pairspecific probes (FAM-labeled probe, uncleaved target present; VIC-labeled probe, template present). Droplets containing an uncleaved or repaired template yield products for both primer pairs. Droplets containing a template that has been cleaved by ciCas9 but not yet repaired are negative for the target amplicon.
We evaluated the performance of DSB-ddPCR at three loci. We employed endonucleases that cleaved the template within the first primer pair and thus simulated a Cas9-mediated DSB. As we expected, uncleaved control DNA yields probe signal for both amplicons, whereas fully digested control DNA yields signal only for the template amplicon (Fig. 2b) . The relationship between observed and expected DSB frequency is linear (Pearson's r 2 > 0.99; Supplementary Fig. 7 ). DSB-ddPCR is also precise; technical replicates are essentially indistinguishable from one another (Supplementary Fig. 7) .
We next compared DSB-ddPCR with other methods for detecting DSBs (Supplementary Table 2 ). Immunodetection methods and the comet assay quantify overall DSB levels but do not reveal where DSBs occur 17, 18 . Sequencing-based methods like BLESS 25 , DSBCapture 24 , and GUIDE-Seq 20 identify DSB locations genome wide; but these methods are complex, expensive, and semiquantitative. qPCR reveals the prevalence of DSBs at a locus of interest relative to a distal control locus 21 . However, absolute quantitation of DSBs, as we show with DSB-ddPCR ( Supplementary  Fig. 7 ), has not been demonstrated. Furthermore, ddPCR offers several inherent advantages over qPCR, including absolute quantification without references, less sensitivity to PCR efficiency, greater precision, and improved reproducibility 33 . Thus, DSB-ddPCR presents a new and more quantitative way to detect DSBs at specific loci.
characterization of dnA cleavage and repair kinetics
Cas9-mediated editing depends on DSB generation and subsequent repair, yet the temporal relationship between these two processes is unclear. To explore this relationship, we conducted time-course experiments using ciCas9 to generate DSBs, DSBddPCR to quantify DSBs, and sequencing to quantify indels. To ensure that protein-DNA complexes (including ciCas9-bound DNA) did not interfere with DSB quantitation, we implemented a 1-h-long proteinase K digestion ( Supplementary Fig. 8 ). We first examined DSB kinetics at the AAVS1, EMX1, and MYC loci ( Fig. 3a and Supplementary Fig. 9 ). In this look at the kinetics of Cas9-mediated DSB generation in cells-which is, to our knowledge, the first of its kind-we observed some features that are common to all three loci. For example, DSBs appear rapidly and reach a maximum well before 24 h. In addition, at all three loci, a large number of unresolved DSBs are present. However, each locus has a distinct DSB kinetic profile. For example, at the AAVS1 locus a maximum of 19.2% (s.e.m. = 1.8%) of templates have DSBs after 2 h; whereas at the EMX1 locus a maximum of 26.2% (s.e.m. = 4.9%) of templates have DSBs after 8 h.
We next examined the relationship between the appearance of DSBs and indels at these three loci (Fig. 3a) . We found that indels are typically generated more slowly than DSBs, and indels appear in an approximately linear fashion in the first 8 h after ciCas9 activation. However, the rate of indel appearance is comparatively slow at the AAVS1 locus, which might be explained by the lower frequency of DSBs. The MYC and EMX1 loci share similar indel kinetics but exhibit distinct DSB profiles. Most indels have appeared at both loci by 8 h; however, during this period, DSB frequency declines appreciably at the MYC locus and increases at the EMX1 locus. Thus, at least for these three loci, Cas9 cleavage and DNA repair rates appear to differ. However, the mechanisms underlying the differences we observe remain unclear.
To investigate events that occur shortly after ciCas9 activation, we performed high-resolution time courses using two adjacent sgRNAs that target the MYC locus (Fig. 3b) . DSBs are present for both sgRNAs after 10 min (one-sided t-test, n = 3; MYC sgRNA4 P = 0.014; MYC sgRNA5 P = 0.007). Interestingly, although MYC sgRNA5 cleaves only ten nucleotides downstream of sgRNA4 on the same strand, we observed distinct kinetic profiles at each target site. Over the first 30 min, cleavage with MYC sgRNA5 is approximately twice as fast as with MYC sgRNA4 (sgRNA5 cleavage = 1.2 ± 0.1 percent per min; sgRNA4 = 0.66 ± 0.09; Supplementary  Fig. 10 ). DSB frequency peaks after 1 h at the sgRNA5 site. DSB frequency peaks after 2 h at the sgRNA4 site, by which time DSB frequency at the sgRNA5 site has already declined considerably. Despite the greater initial DSB generation rate, higher maximum, and earlier decline in DSB frequency, sgRNA5 yields fewer indels after 24 h than does MYC sgRNA4 ( Supplementary Fig. 11 ). One possible explanation for this difference between sgRNAs is that repair kinetics are distinct. Another possibility is that errorfree repair is more prevalent for DSBs generated by sgRNA5. Differences in apparent kinetics and repair outcomes might inhere to differences in the guide sequences themselves or in the immediately adjacent sequence. Finally, loss of MYC impairs cell proliferation 34 , and both sgRNAs target the 5′ UTR of this gene. Thus, the differences between these sgRNAs may relate to proliferation, although proliferation effects are unlikely to appreciably impact early time points. We next compared the DSB generation kinetics of ciCas9 to those of another inducible Cas9 variant, arC9 (ref. 12). arC9 may also be rapidly activatable because, like ciCas9, it is a singlecomponent system activated by the small molecule 4-hydroxytamoxifen. We directly compared ciCas9 with arC9 DSB generation kinetics at the AAVS1 locus (Fig. 3c) . ciCas9, but not arC9, yielded a small but significant increase in DSBs after 10 min (one-sided t-test, n = 3; ciCas9, P = 0.011; arC9, P = 0.13). Furthermore, arC9 suffered from higher basal activity and lower fold activation.
tuning cicas9 specificity, basal activity, and chemical activation We explored the possibility of tuning ciCas9's performance, focusing first on editing specificity. To determine the specificity of ciCas9 relative to that of wild-type Cas9, we measured specificity ratios (i.e., on-target:off-target indel frequency ratios) for four sgRNAs at a total of five off-target sites. We found that ciCas9 had a higher specificity ratio than that of wild-type Cas9 at four of five on-target:off-target pairs ( Fig. 4a and Supplementary  Fig. 12 ). Despite the improved specificity of ciCas9 over that of wild-type Cas9, off-target activity was still detectable at all off-target sites tested. To further improve on-target specificity, we introduced previously identified, specificity-enhancing mutations 3 to yield enhanced-specificity ciCas9 (e-ciCas9). e-ciCas9 had no detectable off-target activity for two of three on-target:off-target pairs, dramatically improving the specificity ratios (Fig. 4a and Supplementary Fig. 13 ). For the third on-target:off-target pair, off-target editing was reduced but still detectable.
To minimize the basal activity of ciCas9, we strengthened the BCL-xL-BH3 peptide interaction using a panel of BH3 variants with increased affinity for BCL-xL (Fig. 4b, Supplementary  Fig. 14, and Supplementary Table 5) . The highest affinity variants, ciCas9(L22) and ciCas9(F22), demonstrated significantly lower basal editing relative to ciCas9 ( Fig. 4c; one-sided t-test; n = 3; L22, P = 0.044; F22, P = 0.039). However, the level of A3-activated editing for both the ciCas9(L22) and ciCas9(F22) was reduced relative to ciCas9. Thus, strengthening the BCL-xL-BH3 interaction reduced basal activity and activation by A3.
One concern regarding the use of small molecules that target BCL-xL, a member of the antiapoptotic BCL-2 family, is the potential for toxicity through the release of proapoptotic factors. However, due to functional redundancy among BCL-2 family members, BCL-2/xL-selective disruptors are not generally cytotoxic 35 . For example, ABT-737 is a BCL-2/xL disruptor that is well tolerated in mice for extended durations and is generally only toxic to cell lines that are primed for death 36, 37 . We chose A3 for this study because it is even more selective for BCL-xL over BCL-2 and MCL-1 than ABT-737. BCL-xL-selective disruptors like A3 are well tolerated in mice, with reversible thrombocytopenia being the sole observed phenotypic effect [38] [39] [40] [41] . Furthermore, we confirmed that A3 does not sensitize cells to the added stress of Cas9-mediated cleavage and has no appreciable effect on the level of DSBs or indels generated by wild-type Cas9 ( Supplementary  Fig. 15 ). Thus, ciCas9 and A3 could be used to investigate Cas9-mediated cleavage and repair in most cell lines or in mice. If the toxicity of BCL-2/xL disruptors has not been determined for a cell line of interest, users should perform studies of cell proliferation and viability before proceeding.
Because BCL-2/xL disruptors are being developed for clinical use, compounds with improved selectivity and drug-like properties continue to appear 35 . Thus, we investigated the effectiveness of different BCL-2-family disruptors in activating ciCas9. Two disruptors, ABT-737 (ref. 42 ) and WEHI-539 (ref. 43) , resulted in robust editing at lower concentrations than A3-this is consistent with their increased cellular potency against BCL-xL (Fig. 5a,b) . The enhanced cellular potency of WEHI-539 also facilitated editing with the most tightly autoinhibited ciCas9 variant, ciCas9(F22) (Fig. 5c) . WEHI-539's greater selectivity for BCL-xL and efficacy in activating ciCas9(F22) makes it an attractive candidate when low basal activity is required. While unfavorable pharmacokinetic properties preclude the use of WEHI-539 in animal models, derivatives like A-1155463 and A-1331852 have comparable BCL-xL affinity and specificity, and they can be used in mice 39, 40 . Furthermore, plasma concentrations of BCLxL disruptors that are sufficient to potently activate ciCas9 can be achieved in mice 40, 44 and humans 45 (Supplementary Table 6 ).
discussion
We developed a rapidly chemically inducible Cas9 variant using intramolecular autoinhibition facilitated through REC2 domain replacement. We anticipate that REC2 domain replacement will complement other approaches like insertion scanning 12 and will thus greatly expand our ability to control Cas9 activity. We also developed DSB-ddPCR-which is, to our knowledge, the first application of ddPCR to measure DSBs. DSB-ddPCR could be used to quantify DSBs generated by mechanisms other than Cas9-mediated DNA cleavage. By combining ciCas9 and DSB-ddPCR, we were able to investigate the previously unexplored kinetic relationship between Cas9-mediated DNA cleavage and repair. We found that DSBs are generated in a matter of minutes, and indels appear in as little as half an hour. While further work is needed to precisely quantify DSB repair rates, our results suggest that repair occurs more rapidly than the long half-life of the Cas9-DSB complex measured in vitro might imply 1, 6 . We also observe an excess of DSBs relative to indels, which might be due to error-free DSB repair 46 .
Our tools give a tantalizing look at the kinetics of Cas9-mediated DSB generation and repair. However, many challenges remain. In addition to the action of ciCas9 and DNA repair machinery, other processes influence the frequency of DSBs and indels we observed. For example, cell proliferation during these experiments may be impacted by transfection or increasing density, which could in turn affect cleavage and repair kinetics. Disruption of some loci, such as MYC, might influence cell proliferation and thus DSB and indel frequency. These additional processes could be accounted for either experimentally or by modeling, which would enable collection and interpretation of longer time courses. A ciCas9 variant that could be inactivated rapidly would enable pulsed DNA cleavage, which would facilitate precise estimation of DSB repair rates and could reveal the prevalence of error-free repair. Furthermore, chemical or genetic perturbation of specific DNA repair pathways could yield mechanistic insight into cleavage and repair kinetics. Ultimately, we envision using ciCas9 and DSB-ddPCR to dissect the influence of chromatin structure, target sequence, and cellular state on the kinetics of Cas9-mediated DSB generation and subsequent repair. methods Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Modeling Cas9 REC2 domain replacement with BCL-xL. Volume estimates for the REC2 (residues 180-307) and BCL-xL (residues 4-198) domains were performed using the 3V volume calculator 47 . Computational modeling of REC2 replacement with BCL-xL was performed using RosettaRemodel 48 . Briefly, BCL-xL (PDB ID: 2BZW) was treated as a rigid body inserted after Cas9 residue 179 and connected to residue 308 of Cas9 with a flexible linker (PDB ID: 4OO8). A blueprint file defined regions to rebuild in a modeling task. The functionality for fusing one structure into another (which is turned on with the -insert_segment_from_pdb flag) uses '0 × I' entries, which denote extensions of the peptide chain from the inserted PDB, in the range that corresponds to the placement of the BCl-xL domain. The flexible linker was composed of repeating glycine-(serine/threonine) residues, and backbone conformations were sampled by introducing random combinations of torsions from loop fragments. To facilitate the conformational search, a random break was made in the flexible linker to be reconnected via both random fragment moves and chain-closure algorithms guided by the Rosetta energy function; trajectories that properly reconnected the chain were considered successful. The lowest energy model from each successful trajectory was saved as a PDB file.
The flags to run the calculations are as follows: -database [rosetta database location]; -s [template Cas9 PDB file] #4OO8, after deletion of REC2, nucleic acids; -remodel:blueprint [blueprint files]; -insert_segment_from_pdb [PDB formatted BCL-xL domain]; -num_trajectory 10; -save_top 1; -remodel:quick_and_ dirty; -use_clusters false; -vall debug1000vall; -overwrite. 300 independent trajectories were sampled in 30 parallel runs that used the flags above.
Cas9, ciCas9, arC9, and sgRNA expression plasmids. An Nterminal FLAG tag sequence was appended via Gibson Assembly Cloning (New England Biosciences) to a human codon optimized Cas9 (subcloned from hCas9, a gift from G. Church, Harvard; Addgene plasmid 41815) with a single C-terminal NLS expressed from a pcDNA3.3-TOPO vector. BCL-xL (residues 4-198, Uniprot Q07817-1), BH3 peptide (APPNLWAAQRYGR ELRRMADEGEGSFK), and linker sequences ( Supplementary  Fig. 3 ) were introduced using gBlocks (Integrated DNA Technologies) and Gibson Assembly Cloning. ciCas9 was subsequently subcloned into the pcDNA5/FRT/TO vector (ThermoFisher). Enhanced-specificity ciCas9, ciCas9(L22), and ciCas9(F22) were generated via restriction digest and NEBuilder HiFi Gibson Cloning (New England Biosciences). To create ciCas9(L22) and ciCas9(F22), we used the two highest affinity BH3 sequences tested in this study (Supplementary Table 5 ). The specificity-enhancing mutations from eSpCas9(1.1) (gift from F. Zhang, Broad Institute, Addgene plasmid 71814) were subcloned into ciCas9 to create enhanced-specificity ciCas9 (e-ciCas9). sgRNA target sequences (Supplementary Data Set 1) -except for VEGFA sgRNAs-were cloned into the gRNA_Cloning Vector according to the hCRISPR gRNA synthesis protocol (https:// www.addgene.org/static/data/93/40/adf4a4fe-5e77-11e2-9c30-003048dd6500.pdf). gRNA_Cloning Vector was a gift from G. Church, Harvard (Addgene plasmid 41824). VEGFA site#2 ('VEGFA sgRNA2') and VEGFA Site#3 ('VEGFA sgRNA3') were gifts from K. Joung, Massachusetts General Hospital (Addgene plasmids 47506 and 47507). arC9 (containing NLS) expression plasmid was a gift from D. Savage, UC Berkeley.
Cell culture. HEK-293T cells (293T/17, ATCC) were maintained in high-glucose DMEM, 10% fetal bovine serum (FBS), 4 mM L-glutamine (Life Technologies). U2OS (ATCC) and HCT116 (ATCC) cells were maintained in McCoy's 5A (Modified) medium, 10% FBS (Life Technologies). Cells were tested and certified free of mycoplasma monthly.
Editing of genomic loci. Cells were plated in 12-well plates at the following densities: HEK-293T 3.25 × 10 5 cells/well; U2OS 7.5 × 10 4 cells/well; HCT116 3.00 × 10 5 cells/well. The day following plating, cells were transfected with Turbofectin 8.0 (Origene)-except as shown in Figure 1d and Supplementary Figures 2 and  6d , where cells were transfected with X-tremeGENE HP. All cells were transfected with 3 µL transfection reagent and 1 µg plasmid DNA per well unless otherwise noted. The plasmid DNA mixture consisted of 450 ng sgRNA plasmid, 450 ng of Cas9 construct plasmid, and 100 ng pMAX-GFP as a transfection control. 24 h after transfection, ciCas9 was activated with the indicated concentrations of A-385358, WEHI-539 (ApexBio Technology), or ABT-737 (Selleck Chemicals). A-385358 was synthesized according to previously reported procedure 41 . The identity of A-385358 was confirmed by 1H-NMR and mass spectrometry (Bruker Esquire Ion Trap MS). >95% purity was confirmed by analytical HPLC. arC9 was activated with 1 µM 4-hydroxytamoxifen (Selleck Chemicals). Compounds were stored as 10 mM stocks in DMSO at -20 °C. Final DMSO concentration in drug-treated wells was 0.1%.
To harvest HEK-293T and HCT116 cells, wells were washed with 1 mL/well ice-cold DPBS. Cells were subsequently harvested via trituration with 600 µL ice-cold DPBS, spun down at 1,500 × g for 10 min at 4 °C, decanted, and cell pellets stored at -80 °C. To enable temporal precision, plates for time-course experiments were placed on ice before harvesting. To harvest U2OS cells, wells were washed with 1 mL prewarmed DPBS, trypsinized (0.25% trypsin-EDTA, Life Technologies), and quenched with 10% -FBSsupplemented DMEM. Cells were spun down at 1,500 × g for 10 min at 4 °C, washed with ice-cold DPBS, spun down at 1,500 × g for 10 min at 4 °C, decanted, and cell pellets stored at -80 °C. For DSB-ddPCR experiments ( Fig. 3; Supplementary Figs. 6c and  9-11 ), transfections were carried out as above, except cells were transfected using 1.5 µL Turbofectin 8.0 transfection reagent using 225 ng sgRNA, 225 ng ciCas9, and 50 ng pMAX-GFP plasmids per well in 12-well plates-this was found to result in low background signal in the absence of Cas9 activity (Supplementary Fig. 9 ). For cell viability experiments (Supplementary Fig. 15 ), cells were transfected using 1.5 µL Turbofectin 8.0 transfection reagent using 225 ng sgRNA, 225 ng ciCas9, and 50 ng pMAX-GFP plasmids per well in 24-well plates (plating density was scaled to 1.625 × 10 5 cells/well).
Insertions or deletions quantification with high-throughput sequencing. Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's instructions with the following modification: proteinase K digestion was extended to 1 h at 56 °C. 20 cycles of primary PCR to amplify the region of interest was performed using 2 µL of DNeasy eluate (~100-300 ng template) in a 5 µL Kapa HiFi HotStart polymerase reaction (Kapa Biosystems; for primers see Supplementary Data Set 1). The PCR reaction was diluted with 45 µL DNAsefree water (Ambion). Illumina adapters and indexing sequences were added via 25 cycles of secondary PCR with 3 µL of diluted primary PCR product in a 10 µL Taq polymerase reaction (New England Biosciences; for primers see Supplementary Data Set 1). The final amplicons were run on a TBE-agarose gel (0.7%); and the product band was excised and extracted using the Freeze and Squeeze Kit according to the manufacturer's instructions (Bio-Rad). Gel-purified amplicons were quantified by qPCR using the Illumina Library Quantification Kit (Kapa Biosystems). Then, up to 300 indexed amplicons were pooled and sequenced on a MiSeq (MiSeq 150 V3 kit, Illumina, for primers see Supplementary Data Set 1).
After demultiplexing of reads (bcl2fastq, Illumina), indels were quantified with a custom Python script that is freely available upon request. Briefly, 8-mer sequences were identified in the reference sequence located 20 bp upstream and downstream of the target sequence. Sequence distal to these 8-mers was trimmed. Reads lacking these 8-mers were discarded. For the VEGFA sgRNA3 OT1 locus, the process was the same, except 20-mer sequences located 10 bp upstream and downstream of the target sequence were used. The trimmed reads were then evaluated for indels using the Python difflib package. Indels were defined as trimmed reads which differed in length from the trimmed reference and for which an insertion or deletion operation spanning or within 1 bp of the predicted Cas9 cleavage site was present. Indel quantification for the initial Cas9. BCL screen ( Supplementary  Fig. 2 ) was performed using an analysis method similar to that previously described 49 . Briefly, reads were aligned to reference using Bowtie 2 (ref. 50). SAMtools 51 was used to generate pileup files, which were used to map and quantify indels.
Droplet digital PCR assay for double-strand breaks. A step-bystep protocol is available in Protocol Exchange 32 . Two amplicons were designed for digital droplet PCR (ddPCR), one including the sgRNA-binding/Cas9 cut site, the other a proximal control uncut site. For the MYC locus, a TaqMan probe (Thermo Fisher Scientific) was designed for each amplicon using Primer 3 (http:// bioinfo.ut.ee/primer3-0.4.0/). Dual-quenched probes were used for the EMX1 and AAVS1 loci (Integrated DNA Technologies). Droplets were created using Droplet-generating oil for probes, DG8 cartridges, DG8 Gaskets and the QX200 Droplet generator (Bio-Rad); amplification was performed using ddPCR Supermix for Probes (Bio-Rad). The ddPCR Supermix amplification reactions were set up according to the manufacturer's specifications (Bio-Rad). 1 µL of DNeasy eluate (~50-150 ng), obtained as described above, was added to a 20 µL amplification reaction with final primer and probe concentrations of 900 nM and 250 nM, respectively. The AAVS1 locus required addition of SmaI and AvrII restriction enzymes (New England BioLabs) to the master mix for better separation of target and template amplicon probe signals (see Bio-Rad instructions). The reaction was divided into droplets for amplification following the manufacturer's protocol (Bio-Rad). Droplets were transferred to a 96-well PCR plate and heat sealed using PX1 PCR plate sealer (Bio-Rad). Droplets were amplified using the following cycling conditions: MYC 95 °C × 10 min, 40 cycles (94 °C × 30 s, 55 °C × 60 s), 98 °C × 10 min, all other amplicons 95 °C × 10 min, 40 cycles (94 °C × 30 s, 60 °C × 60 s), 98 °C × 10 min. Following thermal cycling, droplets were individually scanned using the QX200 Droplet Digital PCR system (Bio-Rad). Positive and negative droplets in each fluorescent channel (VIC/FAM) were distinguished on the basis of fluorescence amplitude using a global threshold set by the minimal, intrinsic fluorescence signal resulting from imperfect quenching of the fluorogenic probes (negative droplets) as compared to the strong fluorescence signal from cleaved probes in droplets with amplified template(s). Cleaved control DNA was created by digesting genomic DNA using the restriction enzyme Sfc-I for the MYC locus, DrdI for the EMX1 locus, and BSU36I for the AAVS1 locus (New England BioLabs) according to the manufacturer's instructions. The DSB frequency in the control and experimental samples was calculated as:
Target template+] Target template+] + Target template
To generate standard curves, restriction-enzyme-digested control DNA was mixed with uncleaved control DNA in defined amounts, DSB frequency was quantified using the ddPCR protocol, and a linear regression was performed. For the time-course experiments, absolute DSB frequencies were calculated by fitting raw frequencies to standard curves.
Western blotting. Cells were harvested as above then lysed in a modified RIPA buffer (50 mM Tris-HCL, pH 7.8, 1% IGEPAL CA-630, 150 mM NaCl, 1 mM EDTA, Pierce Protease Inhibitor Tablet). Lysates were cleared by centrifugation at 17,000 × g for 10 min at 4 °C. Then, samples were incubated at 98 °C for 7 min, subjected to SDS-PAGE (MOPS/SDS running buffer, Criterion and Mini-PROTEAN TGX gels, Bio-Rad) and transferred to nitrocellulose. Blocking and antibody incubation were done in TBS with 0.1% Tween-20 (v/v) and blocking buffer (Odyssey). Primary antibodies were diluted: FLAG (1:1,000, Cell Signaling Technology #8146; or 1:1,000 or Sigma M2 #F1804) and GAPDH (1:2,000, Cell Signaling Technology #2118). Blots were washed in TBS with 0.1% Tween-20. Antibody binding was detected by using near-infrared-dye-conjugated secondary antibodies and visualized on the LI-COR Odyssey scanner. For evaluation of proteinase K digestion efficacy (Supplementary Fig. 8 ), cells from a 12-well plate were split into thirds. One third was processed as described above for DSBddPCR samples. One third was processed as described but was not run on DNeasy column. One third of the cells underwent only the first step in processing-resuspension in PBS and Buffer AL (DNeasy kit)-but was not treated with Proteinase K or run on DNeasy column. Protein was isolated from the three samples using methanol chloroform precipitation, resuspended in 30 µL LDS Sample buffer (ThermoFisher Scientific), supplemented with DTT, and heated to 98 °C for 7 min. 10 µL of each sample was run on a Criterion gel (Bio-Rad), and blots were processed and visualized as described above.
Fluorescence anisotropy BH3 competition assay. Assays were performed as previously described 52 . The BH3 peptide variants (initial concentration = 10 µM, three-fold serial dilutions, ten data points) G22, V22, and A22 (GenScript) were assayed against 38 nM BCL-xL in the presence of 35 nM Bak-BODIPY. The BH3 peptide variants (initial concentration = 10 µM, threefold serial dilutions, ten data points) L22 and F22 (GenScript) were assayed against 12 nM BCL-xL in the presence of 35 nM Bak-BODIPY. Competition assays were incubated at room temperature for 7 h. The amount of polarization was measured in millipolarization (mP) units with an excitation of 485 nm and emission of 530 nm. IC 50 values were determined using Graphpad Prism software (nonlinear regression analysis). For each BH3 variant titration, three technical replicates were performed. The calculated IC 50 values were used to determine K i values (classic model, http://botdb.abcc.ncifcrf.gov/toxin/ kiConverter.jsp) 53 . K i values shown in Supplementary Table 5 are the average of assays performed in triplicate ± s.e.m. (n = 3 technical replicates).
Statistical analysis. Statistical tests of indel and DSB frequency were performed in Excel using a one-sided two-sample Student's t-test. Statistical tests of linear regression slopes were performed in Prism software. A Life Sciences Reporting Summary for this article is available.
Data availability statement. Sequencing data are available at the NCBI Short Read Archive (SRP109554). All other data that support the findings of this study are available from the corresponding authors upon request.
